Hematología y Hemoterapia

Resultados: 338
Tipo Título / Nombre Autor(es) Año
Impact of center characteristics and macroeconimic factors on the outcome of adult patients with acute lymphoblastic leukemia treated with peiatric-inspired protocols Barba P, Morgades M, Montesinos P, González Campos J..., Bergua Burgues J 2022
Pharmacokinetics and pharmacodynamics in first-mind: a phase IB, open-label, randomized study of tafasitamab+ + lenalidomide + R-Chop in patients with newly diagnosed diffuse large B-cell lymphoma Belada D, Kopeckova K, Bergua Burgues J, Stevens D..., Dreyling M 2022
Pharmacokinetics and Pharmacodynamics in First-MIND: A Phase Ib, Open-Label, Randomized Study of Tafasitamab ± Lenalidomide + R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Belada D, Kopeckova K..., Bergua J 2022
Preliminary results of VEN-A-QUI Study: a phase 1-2 trial to assess the safety and efficacy of the combination of azacitidine or low- dose cytarabine with venetoclax and quizartinib in newly diagnosed Bergua Burgues JM, Rodríguez Veiga R, Cano I..., Casas Avilés I 2022
Real life experience using front-line CPX-351 for therapy-related and AML-MRC: results from the spanish Pethema registry Bernal T, Rad G, Laiglesia A de, Benavente C..., Bergua Burgues J 2022
Riñones calcificados Casado Cabanillas V 2022
Midostaurin plus intensive chemotherapy in FLT3 mutated AML De la Fuente A, Diaz Beya M, Beneit P..., Bergua Burgues J 2022
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma Encinas C, Hernandez-Rivas JÁ, Oriol A, Rosiñol L, Blanchard MJ..., Cabrera C, et al 2022
Midostaurin Maintenance versus Allo SCT versus W&W in FLT3-Mutated AML: A “Real-Life” Multicenter Study Fuente A de la, Díaz Beya M..., Bergua J 2022
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C..., Burgues JMB, et al 2022